ProQR Therapeutics N.V.
PRQR
$1.94
$0.052.65%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -1.56% | 29.86% | 183.34% | 417.41% | 587.76% |
| Total Other Revenue | 2.46% | -- | -- | 305.56% | 406.67% |
| Total Revenue | -1.38% | 33.96% | 193.51% | 413.98% | 576.76% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -1.38% | 33.96% | 193.51% | 413.98% | 576.76% |
| SG&A Expenses | -9.18% | -18.43% | 0.03% | -28.12% | -13.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.42% | 15.20% | 46.38% | -1.05% | 27.82% |
| Operating Income | -29.84% | -8.51% | -19.11% | 59.60% | 12.94% |
| Income Before Tax | -27.64% | -68.19% | -49.96% | 64.34% | 12.49% |
| Income Tax Expenses | -- | -100.00% | -- | -371.12% | -- |
| Earnings from Continuing Operations | -27.58% | -68.03% | -51.10% | 66.63% | 12.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.58% | -68.03% | -43.42% | 66.70% | 13.22% |
| EBIT | -29.84% | -8.51% | -19.11% | 59.60% | 12.94% |
| EBITDA | -33.09% | -8.10% | -20.15% | 65.23% | 15.44% |
| EPS Basic | 1.18% | -37.28% | -42.24% | 66.98% | 13.94% |
| Normalized Basic EPS | 1.10% | 10.47% | -10.18% | 64.79% | 18.12% |
| EPS Diluted | -3.24% | -37.28% | -43.29% | 67.37% | 13.94% |
| Normalized Diluted EPS | 1.10% | 10.47% | -10.18% | 64.79% | 18.12% |
| Average Basic Shares Outstanding | 29.09% | 22.42% | 0.84% | 0.90% | 0.85% |
| Average Diluted Shares Outstanding | 29.09% | 22.42% | 0.84% | 0.90% | 0.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |